Chlorthalidone

Thalitone treats hypertension and is adjunctive therapy in adult edema associated with HF, liver cirrhosis or renal disease including nephrotic syndrome. Hemiclor specifically treats adult hypertension and has no labeled edema indication. The selected Ascend generic treats hypertension and adjunctive edema in CHF, hepatic cirrhosis, corticosteroid/estrogen therapy and selected renal disorders. Pediatric safety/effectiveness is not established for these products.

BP lowering belongs to comprehensive cardiovascular management; it is not a promise of unique formulation-specific event prevention. Thalitone explicitly states no controlled risk-reduction trials of that branded formulation. This profile summarizes selected labels, not a complete current hypertension/HF/CKD treatment algorithm. Routine diuresis for physiologic pregnancy edema or prevention of preeclampsia is inappropriate; pregnancy requires separate assessment.

The regimens below are selected label directions; they do not establish mg-for-mg substitutability.

Thalitone: initial 50–100 mg daily or 100 mg on alternate days; adjust by response up to 200 mg daily. Selected Ascend generic: initial 50–100 mg daily or 100 mg on alternate days; some need 150–200 mg at those intervals or up to 200 mg/day, with no usual added response above that. Maintenance is often lower. These are supervised adjunctive edema directions, not hypertension titration targets or a routine pregnancy-edema prescription.

No fixed eGFR/CrCl or hepatic dose-reduction algorithm is supplied by the selected labels. Anuria is contraindicated. Severe renal disease/CKD, HF or volume depletion increases AKI/accumulation risk; periodically monitor and consider withholding/discontinuing with significant worsening. Hepatic disease requires caution because small fluid/electrolyte shifts can precipitate coma. Start at the low end in older adults, and reassess BP/volume/labs after changes rather than applying another product’s dose ceiling.

Use the exact once-daily/morning-with-food directions and supervised alternate-day edema plan when prescribed. Selected labels do not supply a universal missed-dose algorithm; arrange individual instructions and avoid compensatory doubling. Vomiting, diarrhea, markedly reduced intake or dizziness can signal a need for timely volume/electrolyte and medicine review.

Anuria and hypersensitivity to chlorthalidone or other sulfonamide-derived drugs in all three selected labels. Severe renal disease, hepatic dysfunction and electrolyte abnormalities also require careful assessment, but are not converted into an invented universal eGFR contraindication.

The selected standalone chlorthalidone labels have no boxed warning. Do not transfer the pregnancy boxed warning of an azilsartan/chlorthalidone combination to standalone chlorthalidone; standalone pregnancy and fetal/neonatal precautions still matter.

Reported effects include orthostatic dizziness, headache, weakness/cramps, GI upset, electrolyte/metabolic disturbances and photosensitivity/rash. Serious reported effects include cholestatic jaundice, pancreatitis, blood-cell disorders, vasculitis and toxic epidermal necrolysis; systematic incidence estimates are unavailable. Overdose can cause weakness, dizziness and dangerous electrolyte/volume disturbances. Seek urgent clinical/Poison Help advice (U.S. 1-800-222-1222); there is no specific antidote, and supportive fluid/electrolyte treatment must be supervised. Label gastric-lavage language is not a home treatment instruction.

Selected generic notes reduced serum protein-bound iodine without clinical thyroid disturbance; this is a legacy assay warning rather than a diagnosis of hypothyroidism. Chlorthalidone reduces calcium excretion, so interpret hypercalcemia/parathyroid-related findings clinically. Routine monitoring should focus on BP, volume, kidney function and electrolytes rather than a drug concentration target.

Modern Thalitone/Hemiclor labels describe decades of pregnancy observations without an identified major-malformation/miscarriage signal, but thiazide exposure can cause fetal/neonatal jaundice, thrombocytopenia, hypoglycemia and electrolyte effects; placental hypoperfusion is a concern. They say not to use as first-line pregnancy hypertension therapy; thiazides do not prevent or alter the course of preeclampsia. Selected generic uses benefit/risk and clearly-needed language; normal dependent pregnancy edema should not be treated routinely. Chlorthalidone enters milk; modern labels advise against breastfeeding during treatment because of infant accumulation/serious effects, while generic advises choosing whether to stop nursing or drug.

Safety/effectiveness in children is not established in all selected labels; no pediatric dose is supplied. Older adults should usually start at the low end with cautious titration, considering renal/hepatic/cardiac function and other drugs. Monitor renal function and electrolyte/BP effects; greater individual sensitivity is possible.

Anuria is contraindicated; severe renal impairment and CKD require caution and closer follow-up, not an unsupported universal eGFR cutoff. Rising creatinine/BUN, dehydration or important electrolyte changes should trigger reassessment/possible interruption. Hepatic disease increases coma risk from fluid/electrolyte changes. Monitor diabetes, gout/hyperuricemia, lipids and high calcium according to individual risk.

Chlorthalidone increases renal sodium/chloride and water excretion; reduced volume and sodium contribute to antihypertensive effects. Thalitone describes a distal convoluted tubular site, while Hemiclor/generic use older cortical-diluting-segment wording. This mechanistic wording does not establish product equivalence or a separate clinical dosing algorithm.

Duration

Diuresis starts on average around 2.6 hours and can persist up to 72 hours; effect varies and does not authorize arbitrary missed-dose doubling.

Disposition

Approximately 75% protein bound; long plasma half-life around 40–60 hours in these label studies.

Elimination

Primarily unchanged urinary drug; renal impairment can increase cumulative effects.

Thalitone formulation

Povidone is used as a bioavailability enhancer; label explicitly forbids substitution with other chlorthalidone formulations. Do not infer an mg-for-mg switch.

Assess baseline BP/volume, renal function, sodium/potassium/magnesium, interacting drugs and relevant diabetes/gout/liver history. Correct electrolyte deficits and monitor periodically, with added checks after dose changes, illness, excess vomiting or parenteral fluid treatment. Follow orthostatic symptoms, edema/weight when used for edema and renal-function deterioration. Check glucose/lipids, uric acid and calcium as indicated; serum lithium monitoring is required with co-therapy. No universal monitoring interval is supplied.

Know the exact product and prescribed hypertension or edema schedule; Thalitone substitution needs specific prescriber review. Report marked thirst, cramps/weakness, unusual drowsiness, vomiting, palpitations, reduced urine or dizziness. Severe fainting, confusion or cardiac symptoms need urgent care. Discuss lithium, diabetes drugs, supplements/alcohol, kidney/liver disease, gout, allergies and pregnancy/nursing. Do not independently add potassium/salt or double a missed dose; use the individualized plan.

Thalitone 15 mg: white biconvex kidney-shaped tablet marked L / 96; example bottle of 30 NDC 70199-017-30. Manufacturer/distributor is Casper Pharma. The label says Thalitone cannot be substituted with other chlorthalidone formulations.

All three selected products: 20–25°C. Dispense in tight, light-resistant containers with child-resistant closures; selected generic also says protect from light. Keep away from children, check expiry and preserve product identification when tablets or regimens change.